Stay updated on Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Sign up to get notified when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.

Latest updates to the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page
- Check7 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check14 days agoChange DetectedA banner announces an NIH-wide transition to using “Super Intelligence” in place of “Artificial Intelligence.” It appears above the study record’s 403 error message.SummaryDifference1%

- Check21 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the study record page continues to display a 403 error.SummaryDifference0.2%

- Check28 days agoChange DetectedThe revision label in the page footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check49 days agoChange DetectedA 403 Forbidden page is now displayed in place of the study record, presenting the standard error message and site chrome rather than the study details.SummaryDifference17%

- Check70 days agoChange DetectedThe revision tag on the page was updated from v3.6.5 to v3.6.6, replacing the previous revision. This reflects a minor platform update rather than changes to study details or data.SummaryDifference0.1%

Stay in the know with updates to Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.